Tapemark has added several new capabilities for transdermal patches, including the formulation, blending, and coating steps in the patch manufacturing process. Together with its existing converting and packaging services, the company now offers fully-integrated transdermal contract development and manufacturing, from API to the finished transdermal patch. In addition to the investment in new equipment and the facilities build-out currently in progress, the company is adding staff to support the new capabilities.
Andy Rensink, president and chief operating officer of Tapemark, said, “Responding to customer demand for full vertical integration, we’re adding formulation, blending, and coating to our existing superior converting and packaging capabilities. Now we’re a full-service provider in the transdermal space. We anticipate strong growth for Tapemark and for the pharma industry, especially as generic drugs continue their push for market share in transdermal patches.”